Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on MNPR. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research boosted their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright boosted their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Barclays reissued an “overweight” rating and issued a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday. Finally, UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Monopar Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $117.42.

Monopar Therapeutics Stock Up 2.4%

NASDAQ MNPR opened at $113.04 on Thursday. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $124.82. The business has a 50 day moving average price of $96.11 and a two-hundred day moving average price of $71.53. The stock has a market cap of $757.25 million, a PE ratio of -52.09 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. Sell-side analysts anticipate that Monopar Therapeutics will post -2.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC increased its holdings in Monopar Therapeutics by 2.3% in the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares during the last quarter. RA Capital Management L.P. lifted its holdings in Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares during the last quarter. Siren L.L.C. grew its position in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter valued at approximately $18,904,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: BTIG Research raised its price target on MNPR to $133, above the company’s $113.04 reference price, signaling continued confidence in Monopar’s potential. BTIG Research Boosts Monopar Therapeutics Price Target
• Positive Sentiment: HC Wainwright maintained a Buy rating and $125 price target while raising its long-term EPS forecasts for fiscal 2029 to $2.44 from $2.41 and fiscal 2030 to $6.77 from $6.61. The increases suggest analysts still expect substantial future earnings growth, although those estimates are several years out. HC Wainwright Monopar Therapeutics Estimates
• Neutral Sentiment: Monopar’s latest quarterly results modestly exceeded expectations, with EPS of negative $0.62 versus the consensus estimate of negative $0.64. However, the company remains unprofitable, and analysts expect a full-year loss.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to negative $0.90 from negative $0.79, Q4 to negative $1.08 from negative $0.95, FY2026 to negative $3.07 from negative $2.90, and FY2027 to negative $1.46 from negative $1.35. Its FY2028 estimate also declined to $0.87 from $0.91. These revisions point to weaker near-term profitability expectations. HC Wainwright Lowers Monopar Earnings Estimates
• Negative Sentiment: Zacks Research downgraded Monopar from “Strong Buy” to “Hold,” while Cantor cut the stock to “Neutral” because of valuation concerns. The rating changes reduce the immediate analyst support for the shares. Zacks Downgrades Monopar Therapeutics Cantor Cuts Monopar to Neutral

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.